Regeneron Pharmaceuticals (REGN) Other Gross PP&E Adjustments (2010 - 2025)

Regeneron Pharmaceuticals' Other Gross PP&E Adjustments history runs 16 years deep, the most recent figure standing at $7.2 billion for Q4 2025.

• On a quarterly basis, Other Gross PP&E Adjustments rose 13.7% year-over-year to $7.2 billion in Q4 2025; TTM through Dec 2025 was $7.2 billion, a 13.7% increase from a year earlier, with the FY2025 full-year figure at $7.2 billion, up 13.7% from the prior year.
• Other Gross PP&E Adjustments advanced to $7.2 billion in Q4 2025 per REGN's latest filing, from $6.3 billion in the prior quarter.
• Across five years, Other Gross PP&E Adjustments topped out at $7.2 billion in Q4 2025 and bottomed at $4.2 billion in Q4 2021.
• The 5-year median for Other Gross PP&E Adjustments is $5.5 billion (2023), against an average of $5.6 billion.
• Across the five-year window, Other Gross PP&E Adjustments increased 13.25% in 2022 and increased 14.71% in 2023, its largest moves.
• Year by year, Other Gross PP&E Adjustments stood at $4.2 billion in 2021, then climbed by 13.25% to $4.8 billion in 2022, then grew by 14.71% to $5.5 billion in 2023, then rose by 14.06% to $6.3 billion in 2024, then increased by 13.7% to $7.2 billion in 2025.
• Per Business Quant, the three latest REGN Other Gross PP&E Adjustments figures stand at $7.2 billion (Q4 2025), $6.3 billion (Q4 2024), and $5.5 billion (Q4 2023).